HC Deb 19 December 2002 vol 396 cc87-8WS
The Secretary of State for Health (Mr. Alan Milburn):

The sixth report to Parliament on the pharmaceutical price regulation scheme (PPRS) was published today.

The report, entitled "PPRS: Sixth Report to Parliament", covers the management and operation of the 1999 scheme, which was introduced in October 1999 including the delivery of the 4.5 per cent. price cut. It explains the Government's objectives for the scheme and gives consolidated information on company annual financial returns. The report sets out the contribution made to the economy by the UK based pharmaceutical industry and sets out the conclusions of the joint Department of Health and Association of the British Pharmaceutical Industry (ABPI) study into the extent of competition in the supply of branded medicines to the National Health Service.

Copies of the report have been placed in the Library.

The Secretary of State for Health (Mr. Alan Milburn):

The joint Department of Health and Association of the British Pharmaceutical Industry (ABPI) study into the extent of competition in the supply of branded medicines to the NHS was published today.

An integral part of the current pharmaceutical price regulation scheme (PPRS) agreement that took effect on 1 October 1999 is a joint assessment by the Department and the ABPI of the scope, pace and change and practical impact of competition in the supply and use of branded medicines for the NHS. The results of this study will be available to both the Government and the pharmaceutical industry in considering the future direction of policy on the PPRS.

The study comprised seven components and work on each of the components was undertaken jointly by the Department and the ABPI with some elements of the analysis contracted out to third parties. The study allowed an unprecedented level of shared data collection and analysis between the Department and the branded pharmaceutical industry in the UK.

Copies of the study, entitled "PPRS: The Study into the Extent of Competition in the Supply of Branded Medicines to the NHS", have been placed in the

Forward to